250 related articles for article (PubMed ID: 29925295)
1. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
2. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
4. Primary Cutaneous Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring RANBP2-ALK Fusion: Report of an Exceptional Case.
Gadeyne L; Creytens D; Dekeyser S; Van der Meulen J; Haspeslagh M
Am J Dermatopathol; 2022 Apr; 44(4):302-305. PubMed ID: 34816804
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with
Rakheja D; Park JY; Fernandes NJ; Watt TC; Laetsch TW; Collins RRJ
Int J Surg Pathol; 2022 Sep; 30(6):706-715. PubMed ID: 35164578
[TBL] [Abstract][Full Text] [Related]
6. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
7. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
8. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
9. Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.
Chopra S; Maloney N; Wang WL
Brain Tumor Pathol; 2022 Jan; 39(1):35-42. PubMed ID: 34743247
[TBL] [Abstract][Full Text] [Related]
10. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
11. EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors.
Kunimasa K; Hirotsu Y; Kukita Y; Ueda Y; Sato Y; Kimura M; Otsuka T; Hamamoto Y; Tamiya M; Inoue T; Kawamura T; Nishino K; Amemiya K; Goto T; Mochizuki H; Honma K; Omata M; Kumagai T
Cancer Genet; 2021 Aug; 256-257():131-135. PubMed ID: 34130229
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
14. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
15. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
16. Uterine mesenchymal tumors harboring
Kyi C; Friedman CF; Mueller JJ; Benayed R; Ladanyi M; Arcila M; Yang SR; Hensley ML; Chiang S
Gynecol Oncol Rep; 2021 Aug; 37():100852. PubMed ID: 34522753
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
[TBL] [Abstract][Full Text] [Related]
18. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
Craig E; Wiltsie LM; Beaupin LK; Baig A; Kozielski R; Rothstein DH; Li V; Twist CJ; Barth M
J Pediatr Surg; 2021 Dec; 56(12):2364-2371. PubMed ID: 33676744
[TBL] [Abstract][Full Text] [Related]
20. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
Front Oncol; 2021; 11():658327. PubMed ID: 34211840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]